Włladyslława Anna Daniel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Włladyslława Anna Daniel has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Anna Haduch
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland
47 shared publications Jacek Wójcikowski
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
33 shared publications- Marta Kot
Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Kraków, Poland
22 shared publications - Ewa Bromek
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland
21 shared publications - Jacek Wójcikowski
Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
18 shared publications - Przemysław Jan Danek
Department of Pharmacokinetics and Drug Metabolism, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
16 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Pharmacological Reports
- p. 1-12
The effect of repeated administration of lumateperone on cytochrome P450 expression and activity in rat liver
Background Antipsychotic drugs are used for long-term treatment of schizophrenia and other psychotic-related symptoms. Our present work aimed at investigating the effects of chronic administration of the third-generation antipsychotic drug lumateperone on the expression of cytochrome P450 (CYP) enzymes involved in drug metabolism and transcription factors in rat liver. Methods Male Wistar rats received lumateperone (1 mg/kg) once daily for 14 days. 24 h after the last dose, their livers were excised, and CYP enzyme expression and activity were measured. In addition, the expression of transcription factors and serum hormone concentrations were evaluated. Results Lumateperone significantly increased the CYP expression and/or activity of CYP2A, CYP2B, and CYP3A enzymes, but decreased that of CYP2D enzymes. The observed changes in CYP enzymes were in line with alterations in transcription factors: lumateperone elevated the mRNA level of PXR and reduced that of FXR in the liver. Simultaneously, increased corticosterone levels and decreased T4 levels in serum were observed. Conclusion Repeated lumateperone administration modulated the expression and activity of selected hepatic CYP enzymes in rats. These findings indicate biological effects on hepatic drug-metabolizing pathways in a rat model. Relevance to human drug–drug interactions remains to be established in in vitro pharmacokinetic studies. Graphical Abstract
- 26 October 2026
- Published by Springer Nature in Pharmacological Reports
- p. 1-12
Open AccessThe effect of repeated administration of lumateperone on cytochrome P450 expression and activity in rat liver
Background Antipsychotic drugs are used for long-term treatment of schizophrenia and other psychotic-related symptoms. Our present work aimed at investigating the effects of chronic administration of the third-generation antipsychotic drug lumateperone on the expression of cytochrome P450 (CYP) enzymes involved in drug metabolism and transcription factors in rat liver. Methods Male Wistar rats received lumateperone (1 mg/kg) once daily for 14 days. 24 h after the last dose, their livers were excised, and CYP enzyme expression and activity were measured. In addition, the expression of transcription factors and serum hormone concentrations were evaluated. Results Lumateperone significantly increased the CYP expression and/or activity of CYP2A, CYP2B, and CYP3A enzymes, but decreased that of CYP2D enzymes. The observed changes in CYP enzymes were in line with alterations in transcription factors: lumateperone elevated the mRNA level of PXR and reduced that of FXR in the liver. Simultaneously, increased corticosterone levels and decreased T4 levels in serum were observed. Conclusion Repeated lumateperone administration modulated the expression and activity of selected hepatic CYP enzymes in rats. These findings indicate biological effects on hepatic drug-metabolizing pathways in a rat model. Relevance to human drug–drug interactions remains to be established in in vitro pharmacokinetic studies. Graphical Abstract
- Open Access
- 8 May 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (3) , 762-774
The novel third-generation antipsychotic drug brexpiprazole affects hepatic transcription factors, serum hormone levels, and cytochrome P450 enzymes after prolonged treatment: pharmacological significance
Background Brexpiprazole is a third-generation antipsychotic used for the treatment of schizophrenia or as an adjunctive drug for the treatment of affective and neurological disorders. The combined treatments with brexpiprazole and other drugs that are also cytochrome P450 (CYP) substrates may lead to pharmacokinetic drug-drug interactions. Our present work aimed to investigate the effects of prolonged administration of brexpiprazole on the expression of hepatic transcription factors and CYP drug-metabolizing enzymes. Methods Male Wistar rats received brexpiprazole (1 mg/kg ip.) for two weeks. Their livers were excised 24 h after the last dose, and the activities (HPLC), protein levels (Western blotting), and mRNAs (qRT-PCR) of CYP enzymes were measured. In parallel, the expression of hepatic transcription factors (Western blotting, qRT-PCR) and the concentration of serum hormones (ELISA) were assessed. Results Brexpiprazole produced a broad-spectrum effect on CYP expression and activity. It enhanced the expression and activity of CYP1A, CYP2A, CYP3A1/2, and the activity of CYP2B, but decreased the expression/activity of CYP2Ds and CYP2E1. The observed changes in CYP enzymes corresponded to alterations in transcription factors: the increased expression of PXR and AhR, and decreased expression of PPARγ, LXR, and FXR. The above modifications in CYP enzymes’ expression were accompanied by enhanced corticosterone and reduced T4 serum levels. Conclusions Brexpiprazole affects the expression of hepatic transcription factors and CYP, which may impact its own biotransformation and the metabolism of endogenous substances and concomitantly administered drugs, and lead to drug-drug interactions of pharmacological/clinical importance.
- 8 May 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (3) , 762-774
Open AccessThe novel third-generation antipsychotic drug brexpiprazole affects hepatic transcription factors, serum hormone levels, and cytochrome P450 enzymes after prolonged treatment: pharmacological significance
Background Brexpiprazole is a third-generation antipsychotic used for the treatment of schizophrenia or as an adjunctive drug for the treatment of affective and neurological disorders. The combined treatments with brexpiprazole and other drugs that are also cytochrome P450 (CYP) substrates may lead to pharmacokinetic drug-drug interactions. Our present work aimed to investigate the effects of prolonged administration of brexpiprazole on the expression of hepatic transcription factors and CYP drug-metabolizing enzymes. Methods Male Wistar rats received brexpiprazole (1 mg/kg ip.) for two weeks. Their livers were excised 24 h after the last dose, and the activities (HPLC), protein levels (Western blotting), and mRNAs (qRT-PCR) of CYP enzymes were measured. In parallel, the expression of hepatic transcription factors (Western blotting, qRT-PCR) and the concentration of serum hormones (ELISA) were assessed. Results Brexpiprazole produced a broad-spectrum effect on CYP expression and activity. It enhanced the expression and activity of CYP1A, CYP2A, CYP3A1/2, and the activity of CYP2B, but decreased the expression/activity of CYP2Ds and CYP2E1. The observed changes in CYP enzymes corresponded to alterations in transcription factors: the increased expression of PXR and AhR, and decreased expression of PPARγ, LXR, and FXR. The above modifications in CYP enzymes’ expression were accompanied by enhanced corticosterone and reduced T4 serum levels. Conclusions Brexpiprazole affects the expression of hepatic transcription factors and CYP, which may impact its own biotransformation and the metabolism of endogenous substances and concomitantly administered drugs, and lead to drug-drug interactions of pharmacological/clinical importance.
- Open Access
- 11 March 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (3) , 808-825
The effect of salidroside, an active component of Rhodiola rosea, on the metabolic activity of rat and human cytochromes P450 in preclinical studies
Salidroside (SAL) is the active ingredient of the traditional adaptogenic herb Rhodiola rosea. Cytochromes P450 (P450), crucial enzymes in drug metabolism, are central to understanding drug–herb interactions. This study investigates the impact of SAL on the metabolic activity of selected P450 in both rat and human systems. Wistar rats were administered intragastrically with SAL 5, 15, or 45 mg/kg/day for seven days. The metabolic activity of CYP1A2, CYP2C6, CYP2D, and CYP3A was measured in rat liver microsomes (RLMs). Amounts and gene expressions of CYP1A2 and CYP2C6 were assessed in RLMs using Western blot and two-step qRT-PCR. rPXR, hPXR, and CAR3 gene reporter assays were conducted. The in vitro inhibitory studies of SAL in both drug-naïve rat and human liver microsomes were performed. Interactions between SAL and human P450 were also studied by in silico methods. SAL at the dose of 5 mg/kg/day slightly increased the specific activity of the P450 studied. However, SAL did not change either the P450 protein levels or the expression of the corresponding genes in rat liver. It also did not cause direct inhibition of rat and human P450 in liver microsomes in vitro. Molecular docking with human P450 confirmed these findings. Moreover, SAL inhibited the agonist-mediated induction of both rat and human PXR. Based on our findings, SAL is unlikely to pose a significant risk of P450-mediated drug-herb interactions and rather preserves the constitutional CYP3A metabolic activity via interaction with PXR. Not applicable. The online version contains supplementary material available at 10.1007/s43440-026-00842-w.
- 11 March 2026
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (3) , 808-825
Open AccessThe effect of salidroside, an active component of Rhodiola rosea, on the metabolic activity of rat and human cytochromes P450 in preclinical studies
Salidroside (SAL) is the active ingredient of the traditional adaptogenic herb Rhodiola rosea. Cytochromes P450 (P450), crucial enzymes in drug metabolism, are central to understanding drug–herb interactions. This study investigates the impact of SAL on the metabolic activity of selected P450 in both rat and human systems. Wistar rats were administered intragastrically with SAL 5, 15, or 45 mg/kg/day for seven days. The metabolic activity of CYP1A2, CYP2C6, CYP2D, and CYP3A was measured in rat liver microsomes (RLMs). Amounts and gene expressions of CYP1A2 and CYP2C6 were assessed in RLMs using Western blot and two-step qRT-PCR. rPXR, hPXR, and CAR3 gene reporter assays were conducted. The in vitro inhibitory studies of SAL in both drug-naïve rat and human liver microsomes were performed. Interactions between SAL and human P450 were also studied by in silico methods. SAL at the dose of 5 mg/kg/day slightly increased the specific activity of the P450 studied. However, SAL did not change either the P450 protein levels or the expression of the corresponding genes in rat liver. It also did not cause direct inhibition of rat and human P450 in liver microsomes in vitro. Molecular docking with human P450 confirmed these findings. Moreover, SAL inhibited the agonist-mediated induction of both rat and human PXR. Based on our findings, SAL is unlikely to pose a significant risk of P450-mediated drug-herb interactions and rather preserves the constitutional CYP3A metabolic activity via interaction with PXR. Not applicable. The online version contains supplementary material available at 10.1007/s43440-026-00842-w.
- Open Access
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10488
The Differential Involvement of α1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs
We investigated whether the functional involvement of α1-adrenergic receptors (α1-AR) in the effects induced by antidepressant drugs, desipramine, and milnacipran varies depending on the α1-AR subtype. First, using a mouse line with triple knockout (KO) of genes encoding all three α1-AR subtypes (ABD-KO) and autoradiographic analysis, we demonstrated that the inactivation of α1-AR did not affect the density of other types of adrenergic receptors, α2- and β-AR in the mouse brain. Subsequently, we utilized three mouse knockout lines with selective knockout of the gene encoding a single α1-adrenergic receptor subtype (A-KO, B-KO, and D-KO). We analyzed the impact of these mutations on tissue levels of monoaminergic neurotransmitters in the hypothalamus (HY). Next, we assessed how a specific mutation affects the chronic effects of desipramine and milnacipran in the selected brain regions of male and female mice at various molecular levels: mRNA expression of genes encoding for α1-AR subtypes, gene expression profiling, and phosphorylation of selected signaling proteins (ERK1/2, Akt, GSK3β). The main finding is that the deletion of the α1D subtype predominantly reduced the chronic effects of milnacipran at the examined transcriptomic and proteomic levels. The pattern of changes differed by gender. Our study revealed the functional diversity between α1-AR subtypes in the molecular mechanisms of antidepressants’ drug action.
- 28 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10488
Open AccessThe Differential Involvement of α1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs
We investigated whether the functional involvement of α1-adrenergic receptors (α1-AR) in the effects induced by antidepressant drugs, desipramine, and milnacipran varies depending on the α1-AR subtype. First, using a mouse line with triple knockout (KO) of genes encoding all three α1-AR subtypes (ABD-KO) and autoradiographic analysis, we demonstrated that the inactivation of α1-AR did not affect the density of other types of adrenergic receptors, α2- and β-AR in the mouse brain. Subsequently, we utilized three mouse knockout lines with selective knockout of the gene encoding a single α1-adrenergic receptor subtype (A-KO, B-KO, and D-KO). We analyzed the impact of these mutations on tissue levels of monoaminergic neurotransmitters in the hypothalamus (HY). Next, we assessed how a specific mutation affects the chronic effects of desipramine and milnacipran in the selected brain regions of male and female mice at various molecular levels: mRNA expression of genes encoding for α1-AR subtypes, gene expression profiling, and phosphorylation of selected signaling proteins (ERK1/2, Akt, GSK3β). The main finding is that the deletion of the α1D subtype predominantly reduced the chronic effects of milnacipran at the examined transcriptomic and proteomic levels. The pattern of changes differed by gender. Our study revealed the functional diversity between α1-AR subtypes in the molecular mechanisms of antidepressants’ drug action.
- 6 August 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (9) , 100143
The neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus
- 6 August 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (9) , 100143
The neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus
- Open Access
- 30 May 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (4) , 1142
Correction: Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
- 30 May 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (4) , 1142
Open AccessCorrection: Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
- 11 March 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 689-702
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Background Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide analogs of the modern multitarget antipsychotics aripiprazole and brexpiprazole, compounds PZ-1262 and PZ-1264. We hypothesized that the 4-isoquinolinesulfonamide moiety, derived from the structure of 5-HT6 receptor antagonists, would provide compounds with enhanced activity at 5-HT6 receptors, along with partial agonistic activity at 5-HT1A and D2 receptors. Methods The receptor binding profile, functional activity, and metabolic stability of PZ-1262 and PZ-1264 were evaluated through in vitro assays. Potential antipsychotic, antidepressant, anxiolytic, and pro-cognitive effects were assessed using in vivo behavioral tests in rodents. Results In vitro, PZ compounds demonstrated partial agonistic activity at 5-HT1A receptor, antagonistic activity at D2 and D3 as well as 5-HT2A, 5-HT6 and 5-HT7 receptors and metabolic stability. In vivo, both compounds enhanced phencyclidine-induced hyperactivity in rats and decreased immobility time in the forced swim test in mice, without influencing spontaneous locomotor activity. In the novel object recognition test in rats, they demonstrated pro-cognitive effects in phencyclidine disturbed conditions. PZ-1262 potentiated D-amphetamine-induced hyperactivity, exhibited anxiolytic-like effects in the four plates test in mice, and demonstrated significant brain penetration. Conclusions The complex pharmacodynamic profile translated into the useful psychotropic effects. While the compounds potentiated D-amphetamine- and phencyclidine-induced hyperactivity, this action could be regarded as a desired activating effect rather than evidence against antipsychotic-like efficacy. Present findings point to PZ-1262 as a more promising lead compound for further research.
- 11 March 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (3) , 689-702
Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models
Background Novel antipsychotics are characterized by multitarget profile of action, affecting among others, dopamine and serotonin receptors. In a series of experiments, we designed, synthesized and examined two new isoquinoline-sulfonamide analogs of the modern multitarget antipsychotics aripiprazole and brexpiprazole, compounds PZ-1262 and PZ-1264. We hypothesized that the 4-isoquinolinesulfonamide moiety, derived from the structure of 5-HT6 receptor antagonists, would provide compounds with enhanced activity at 5-HT6 receptors, along with partial agonistic activity at 5-HT1A and D2 receptors. Methods The receptor binding profile, functional activity, and metabolic stability of PZ-1262 and PZ-1264 were evaluated through in vitro assays. Potential antipsychotic, antidepressant, anxiolytic, and pro-cognitive effects were assessed using in vivo behavioral tests in rodents. Results In vitro, PZ compounds demonstrated partial agonistic activity at 5-HT1A receptor, antagonistic activity at D2 and D3 as well as 5-HT2A, 5-HT6 and 5-HT7 receptors and metabolic stability. In vivo, both compounds enhanced phencyclidine-induced hyperactivity in rats and decreased immobility time in the forced swim test in mice, without influencing spontaneous locomotor activity. In the novel object recognition test in rats, they demonstrated pro-cognitive effects in phencyclidine disturbed conditions. PZ-1262 potentiated D-amphetamine-induced hyperactivity, exhibited anxiolytic-like effects in the four plates test in mice, and demonstrated significant brain penetration. Conclusions The complex pharmacodynamic profile translated into the useful psychotropic effects. While the compounds potentiated D-amphetamine- and phencyclidine-induced hyperactivity, this action could be regarded as a desired activating effect rather than evidence against antipsychotic-like efficacy. Present findings point to PZ-1262 as a more promising lead compound for further research.
- Open Access
- 18 February 2025
- Published by MDPI AG in Preprints.org
The Differential Involvement of Alpha1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs
We investigated whether the functional involvement of α1-adrenergic receptors (α1-AR) in the effects induced by antidepressant drugs, desipramine, and milnacipran varies depending on the α1-AR subtype. First, using a mouse line with triple knockout (KO) of genes encoding all three α1-AR subtypes (ABD-KO) and autoradiographic analysis, we demonstrated that the inactivation of α1-AR did not affect the density of other types of adrenergic receptors, α2- and β-AR in the mouse brain. Subsequently, we utilized three mouse knockout lines with selective inactivation of the gene encoding a single α1-adrenergic receptor subtype (A-KO, B-KO, and D-KO). We analyzed the impact of these mutations on tissue levels of monoaminergic neurotransmitters in the hypothalamus. Next, we assessed how a specific mutation affects the long-term effects of desipramine and milnacipran in the selected brain regions of male and female mice at various molecular levels: mRNA expression of α1-AR subtypes, gene expression profiling, and activation of selected signaling proteins (ERK1/2, Akt, GSK3). The main finding is that the inactivation of the α1D subtype modulates at various molecular levels the long-term effects of desipramine or milnacipran in a sex-dependent manner. Our study revealed the functional diversity between α1-AR subtypes in the molecular mechanisms of antidepressants’ drug action.
- 18 February 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Differential Involvement of Alpha1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs
We investigated whether the functional involvement of α1-adrenergic receptors (α1-AR) in the effects induced by antidepressant drugs, desipramine, and milnacipran varies depending on the α1-AR subtype. First, using a mouse line with triple knockout (KO) of genes encoding all three α1-AR subtypes (ABD-KO) and autoradiographic analysis, we demonstrated that the inactivation of α1-AR did not affect the density of other types of adrenergic receptors, α2- and β-AR in the mouse brain. Subsequently, we utilized three mouse knockout lines with selective inactivation of the gene encoding a single α1-adrenergic receptor subtype (A-KO, B-KO, and D-KO). We analyzed the impact of these mutations on tissue levels of monoaminergic neurotransmitters in the hypothalamus. Next, we assessed how a specific mutation affects the long-term effects of desipramine and milnacipran in the selected brain regions of male and female mice at various molecular levels: mRNA expression of α1-AR subtypes, gene expression profiling, and activation of selected signaling proteins (ERK1/2, Akt, GSK3). The main finding is that the inactivation of the α1D subtype modulates at various molecular levels the long-term effects of desipramine or milnacipran in a sex-dependent manner. Our study revealed the functional diversity between α1-AR subtypes in the molecular mechanisms of antidepressants’ drug action.
- Open Access
- 4 November 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 76 (6) , 1482-1488
LY354740, an agonist of glutamatergic metabotropic receptor mGlu2/3 increases the cytochrome P450 2D (CYP2D) activity in the frontal cortical area of rat brain
Background: Our previous studies indicated that changes in the functioning of the brain glutamatergic system involving the NMDA receptor may affect cytochrome P450 2D (CYP2D) in the brain. Since CYP2D may contribute to the metabolism of neurotransmitters and neurosteroids engaged in the pathology and pharmacology of neuropsychiatric diseases, in the present work we have investigated the effect of compound LY354740, an agonist of glutamatergic metabotropic receptor mGlu2/3, on brain and liver CYP2D. Methods: The activity (high performance liquid chromatography with fluorescence detection) and protein levels (Western blotting) of CYP2D were measured in the microsomes from the liver and different brain areas of male Wistar rats after 5 day-treatment with LY354740 (10 mg/kg ip). The results were analyzed statistically using Student’s t-test. Results: Among the investigated brain areas, the highest CYP2D activity was found in the cerebellum and brainstem, which exceeded that in the thalamus, cortex, hippocampus and frontal cortex. The mGlu2/3 receptor agonist LY354740 administered for five consecutive days significantly increased the protein level and activity of CYP2D in the frontal cortex. Such a tendency was also observed in the other brain areas. LY354740 did not affect the CYP2D activity in the liver. Conclusions: Repeated administration of the mGlu2/3 receptor agonist, the compound LY354740 specifically increases the protein level and activity of CYP2D in the frontal cortex, which may accelerate dopamine synthesis via an alternative CYP2D-mediated route in the mesocortical dopaminergic pathway, and thus may contribute to the beneficial pharmacological effect on negative symptoms of schizophrenia.
- 4 November 2024
- Published by Springer Nature in Pharmacological Reports
- Vol. 76 (6) , 1482-1488
Open AccessLY354740, an agonist of glutamatergic metabotropic receptor mGlu2/3 increases the cytochrome P450 2D (CYP2D) activity in the frontal cortical area of rat brain
Background: Our previous studies indicated that changes in the functioning of the brain glutamatergic system involving the NMDA receptor may affect cytochrome P450 2D (CYP2D) in the brain. Since CYP2D may contribute to the metabolism of neurotransmitters and neurosteroids engaged in the pathology and pharmacology of neuropsychiatric diseases, in the present work we have investigated the effect of compound LY354740, an agonist of glutamatergic metabotropic receptor mGlu2/3, on brain and liver CYP2D. Methods: The activity (high performance liquid chromatography with fluorescence detection) and protein levels (Western blotting) of CYP2D were measured in the microsomes from the liver and different brain areas of male Wistar rats after 5 day-treatment with LY354740 (10 mg/kg ip). The results were analyzed statistically using Student’s t-test. Results: Among the investigated brain areas, the highest CYP2D activity was found in the cerebellum and brainstem, which exceeded that in the thalamus, cortex, hippocampus and frontal cortex. The mGlu2/3 receptor agonist LY354740 administered for five consecutive days significantly increased the protein level and activity of CYP2D in the frontal cortex. Such a tendency was also observed in the other brain areas. LY354740 did not affect the CYP2D activity in the liver. Conclusions: Repeated administration of the mGlu2/3 receptor agonist, the compound LY354740 specifically increases the protein level and activity of CYP2D in the frontal cortex, which may accelerate dopamine synthesis via an alternative CYP2D-mediated route in the mesocortical dopaminergic pathway, and thus may contribute to the beneficial pharmacological effect on negative symptoms of schizophrenia.